Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The analysis of short-term operating activity reveals a significant lengthening of the cash conversion process over the five-year period from 2019 to 2023. This trend is primarily driven by a deceleration in inventory movement, which offsets minor improvements in receivables collection efficiency.
- Inventory Management
- A consistent decline in inventory turnover is observed, falling from 1.41 in 2019 to 1.00 in 2023. This corresponds to a substantial increase in the average inventory processing period, which rose from 258 days to 365 days. The data indicates a trend toward slower inventory liquidation and an increase in the duration that capital remains tied up in stock.
- Receivables and Collections
- Receivables management has demonstrated stability and slight improvement. The receivables turnover ratio increased from 5.76 in 2019 to 6.55 in 2023, while the average receivable collection period decreased from 63 days to 56 days. This suggests an increased efficiency in converting credit sales into cash.
- Payables and Liabilities
- The average payables payment period exhibited volatility, peaking at 81 days in 2020 before normalizing to 59 days by 2023. This indicates a temporary extension of payment terms in 2020, followed by a return to a payment cadence similar to the 55 days observed in 2019.
- Operating and Cash Conversion Cycles
- The operating cycle expanded significantly from 321 days in 2019 to 421 days in 2023. This expansion is mirrored in the cash conversion cycle, which increased from 266 days to 362 days. The growth in these cycles is almost entirely attributable to the lengthening inventory processing period, indicating a less efficient overall cash flow cycle from the purchase of materials to the collection of cash from sales.
- Working Capital Efficiency
- Working capital turnover experienced a decline from 2.13 in 2019 to a low of 1.50 in 2020, before recovering to 1.92 by 2023. Although the ratio recovered partially, it remains below 2019 levels, reflecting the increased investment in working capital relative to sales revenue.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Inventory Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | 2,561) | 2,454) | 2,303) | 2,057) | 1,992) | |
| Inventories | 2,564) | 2,345) | 1,923) | 1,628) | 1,410) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 1.00 | 1.05 | 1.20 | 1.26 | 1.41 | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.98 | 4.87 | 5.58 | — | — | |
| Amgen Inc. | 0.89 | 1.30 | 1.58 | — | — | |
| Bristol-Myers Squibb Co. | 4.02 | 4.33 | 4.74 | — | — | |
| Danaher Corp. | 3.80 | 4.03 | 4.16 | — | — | |
| Eli Lilly & Co. | 1.23 | 1.54 | 1.88 | — | — | |
| Gilead Sciences Inc. | 3.64 | 3.75 | 4.08 | — | — | |
| Johnson & Johnson | 2.37 | 2.49 | 2.87 | — | — | |
| Merck & Co. Inc. | 2.54 | 2.95 | 2.29 | — | — | |
| Pfizer Inc. | 2.45 | 3.82 | 3.40 | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.70 | 0.65 | 1.25 | — | — | |
| Thermo Fisher Scientific Inc. | 5.06 | 4.60 | 3.88 | — | — | |
| Vertex Pharmaceuticals Inc. | 1.71 | 2.35 | 2.56 | — | — | |
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 2.55 | 3.06 | 3.11 | — | — | |
| Inventory Turnover, Industry | ||||||
| Health Care | 7.36 | 7.85 | 7.90 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Inventory turnover = Cost of sales ÷ Inventories
= 2,561 ÷ 2,564 = 1.00
2 Click competitor name to see calculations.
An analysis of the operating activity ratios from 2019 to 2023 reveals a consistent decline in inventory management efficiency. While the cost of sales has grown steadily, the growth in inventory levels has outpaced this increase, resulting in a downward trend in the inventory turnover ratio.
- Cost of Sales Trend
- The cost of sales exhibited a continuous upward trajectory over the five-year period, rising from 1,992 million USD in 2019 to 2,561 million USD in 2023. This represents a steady expansion in the volume or cost of goods sold during this timeframe.
- Inventory Level Growth
- Inventories grew more aggressively than the cost of sales, increasing from 1,410 million USD in 2019 to 2,564 million USD in 2023. The most significant absolute increase occurred between 2021 and 2022, where inventories rose by 422 million USD.
- Inventory Turnover Ratio Analysis
- The inventory turnover ratio declined every year, moving from 1.41 in 2019 to 1.00 in 2023. This persistent decrease indicates that inventory is remaining in stock longer before being sold, reflecting a reduction in the velocity of inventory conversion.
The divergence between the steady growth of sales costs and the rapid accumulation of inventory suggests a potential shift in supply chain strategy, such as strategic stockpiling, or a decrease in demand relative to production levels.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Receivables Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 8,544) | 8,080) | 7,776) | 6,675) | 6,260) | |
| Accounts receivable, less allowance for doubtful accounts | 1,304) | 1,215) | 1,133) | 1,013) | 1,086) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 6.55 | 6.65 | 6.86 | 6.59 | 5.76 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.87 | 5.16 | 5.63 | — | — | |
| Amgen Inc. | 3.70 | 4.46 | 4.96 | — | — | |
| Bristol-Myers Squibb Co. | 4.93 | 5.48 | 5.65 | — | — | |
| Danaher Corp. | 6.09 | 6.40 | 6.36 | — | — | |
| Eli Lilly & Co. | 3.75 | 4.14 | 4.24 | — | — | |
| Gilead Sciences Inc. | 5.78 | 5.65 | 6.01 | — | — | |
| Johnson & Johnson | 5.73 | 5.88 | 6.14 | — | — | |
| Merck & Co. Inc. | 5.81 | 6.27 | 5.28 | — | — | |
| Pfizer Inc. | 5.33 | 9.24 | 7.16 | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.31 | 2.28 | 2.66 | — | — | |
| Thermo Fisher Scientific Inc. | 5.21 | 5.53 | 4.92 | — | — | |
| Vertex Pharmaceuticals Inc. | 6.31 | 6.19 | 6.66 | — | — | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.96 | 5.76 | 5.54 | — | — | |
| Receivables Turnover, Industry | ||||||
| Health Care | 7.66 | 8.22 | 8.00 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Receivables turnover = Revenue ÷ Accounts receivable, less allowance for doubtful accounts
= 8,544 ÷ 1,304 = 6.55
2 Click competitor name to see calculations.
Between 2019 and 2023, a consistent upward trajectory in revenue is observed, increasing from 6,260 million US$ to 8,544 million US$. During the same period, net accounts receivable followed a general growth pattern, rising from 1,086 million US$ to 1,304 million US$, despite a marginal decrease observed in 2020.
- Receivables Turnover Trend
- A notable improvement in collection efficiency occurred between 2019 and 2021, during which the receivables turnover ratio rose from 5.76 to a peak of 6.86. This suggests that revenue growth significantly outpaced the accumulation of receivables during this initial phase.
- Recent Performance Moderation
- From 2021 to 2023, a slight downward trend is observed, with the turnover ratio moderating from 6.86 to 6.55. This indicates a minor deceleration in the speed of receivable conversions or a slight increase in the average collection period as the scale of operations expanded.
- Comparative Efficiency Analysis
- Despite the marginal decline since 2021, the turnover ratio remains consistently higher than the 2019 baseline of 5.76. The relative stability of the ratio between 2020 and 2023 suggests a disciplined approach to credit management, maintaining a consistent relationship between sales volume and the outstanding receivables balance.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Payables Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | 2,561) | 2,454) | 2,303) | 2,057) | 1,992) | |
| Accounts payable | 411) | 405) | 436) | 457) | 301) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 6.23 | 6.06 | 5.28 | 4.50 | 6.62 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.54 | 5.94 | 6.05 | — | — | |
| Amgen Inc. | 5.32 | 4.08 | 4.72 | — | — | |
| Bristol-Myers Squibb Co. | 3.28 | 3.33 | 3.37 | — | — | |
| Danaher Corp. | 5.58 | 5.45 | 4.48 | — | — | |
| Eli Lilly & Co. | 2.73 | 3.43 | 4.38 | — | — | |
| Gilead Sciences Inc. | 11.81 | 6.25 | 9.36 | — | — | |
| Johnson & Johnson | 2.76 | 2.66 | 2.70 | — | — | |
| Merck & Co. Inc. | 4.11 | 4.08 | 2.96 | — | — | |
| Pfizer Inc. | 3.72 | 5.04 | 5.53 | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.99 | 2.65 | 4.32 | — | — | |
| Thermo Fisher Scientific Inc. | 8.97 | 7.67 | 6.83 | — | — | |
| Vertex Pharmaceuticals Inc. | 3.46 | 3.55 | 4.64 | — | — | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.25 | 4.28 | 4.23 | — | — | |
| Payables Turnover, Industry | ||||||
| Health Care | 5.97 | 5.79 | 5.84 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Payables turnover = Cost of sales ÷ Accounts payable
= 2,561 ÷ 411 = 6.23
2 Click competitor name to see calculations.
An analysis of the short-term operating activity reveals a period of volatility in payables management between 2019 and 2023, characterized by a significant shift in payment efficiency and supplier obligations during the early part of the period, followed by a steady return toward historical norms.
- Cost of Sales Trend
- A consistent upward trajectory in the cost of sales is observed, rising from US$ 1,992 million in 2019 to US$ 2,561 million in 2023. This sustained growth indicates an expansion in operational scale and procurement volume over the five-year period.
- Accounts Payable Dynamics
- Accounts payable experienced a sharp increase in 2020, rising from US$ 301 million to US$ 457 million. Following this peak, a gradual decline was observed through 2022, before the balance stabilized at US$ 411 million by the end of 2023. This suggests a period of increased reliance on supplier credit in 2020, followed by a moderate correction in the liability level.
- Payables Turnover Analysis
- The payables turnover ratio exhibited a V-shaped pattern. After starting at 6.62 in 2019, the ratio declined significantly to 4.50 in 2020, indicating a slower payment cycle and a longer duration for settling supplier obligations. From 2021 onward, a consistent recovery is evident, with the ratio increasing to 5.28, 6.06, and finally 6.23 in 2023. This trend demonstrates a systematic acceleration in the payment of obligations, bringing the turnover rate close to its 2019 baseline.
The correlation between the rising cost of sales and the recovering turnover ratio indicates that while the volume of business increased, the company successfully optimized its payment velocity after the 2020 dip. The synchronization of increasing costs and increasing turnover suggests a disciplined approach to working capital management in the latter three years of the period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Working Capital Turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 6,343) | 7,506) | 6,930) | 6,611) | 4,748) | |
| Less: Current liabilities | 1,889) | 3,167) | 1,797) | 2,170) | 1,806) | |
| Working capital | 4,454) | 4,339) | 5,133) | 4,441) | 2,942) | |
| Revenue | 8,544) | 8,080) | 7,776) | 6,675) | 6,260) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 1.92 | 1.86 | 1.51 | 1.50 | 2.13 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 2.25 | 3.82 | 3.37 | — | — | |
| Bristol-Myers Squibb Co. | 4.60 | 8.30 | 3.95 | — | — | |
| Danaher Corp. | 4.22 | 4.20 | 8.40 | — | — | |
| Eli Lilly & Co. | — | 31.84 | 8.33 | — | — | |
| Gilead Sciences Inc. | 5.61 | 8.42 | 8.54 | — | — | |
| Johnson & Johnson | 11.81 | — | 5.95 | — | — | |
| Merck & Co. Inc. | 9.29 | 5.16 | 7.62 | — | — | |
| Pfizer Inc. | — | 11.09 | 4.83 | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.82 | 0.96 | 1.59 | — | — | |
| Thermo Fisher Scientific Inc. | 4.05 | 5.46 | 5.87 | — | — | |
| Vertex Pharmaceuticals Inc. | 0.93 | 0.85 | 1.02 | — | — | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.68 | 7.25 | 5.87 | — | — | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 10.99 | 11.30 | 8.57 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Working capital turnover = Revenue ÷ Working capital
= 8,544 ÷ 4,454 = 1.92
2 Click competitor name to see calculations.
The analysis of working capital turnover from 2019 to 2023 reveals a period of volatility followed by a trend of efficiency recovery. While revenue demonstrated consistent year-over-year growth, the efficiency of working capital utilization experienced a significant dip before trending upward in the most recent periods.
- Revenue and Working Capital Trends
- Revenue grew steadily from US$ 6,260 million in 2019 to US$ 8,544 million in 2023. In contrast, working capital exhibited a non-linear trend, increasing sharply from US$ 2,942 million in 2019 to a peak of US$ 5,133 million in 2021. Following this peak, working capital decreased and stabilized, closing 2023 at US$ 4,454 million.
- Working Capital Turnover Dynamics
- The working capital turnover ratio declined from 2.13 in 2019 to 1.50 in 2020 and remained stagnant at 1.51 in 2021. This downward movement indicates that the expansion of working capital significantly outpaced revenue growth during this period, resulting in lower operational efficiency. However, a recovery is observed in the subsequent two years, with the ratio rising to 1.86 in 2022 and 1.92 in 2023.
- Operational Efficiency Analysis
- The recent upward trajectory in the turnover ratio suggests an improvement in the ability to generate sales relative to the investment in short-term assets. By reducing the working capital base while continuing to scale revenue, the company has enhanced its operational leaness, moving back toward the higher efficiency levels recorded at the start of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Inventory Processing Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 1.00 | 1.05 | 1.20 | 1.26 | 1.41 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 365 | 349 | 305 | 289 | 258 | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | 73 | 75 | 65 | — | — | |
| Amgen Inc. | 411 | 281 | 231 | — | — | |
| Bristol-Myers Squibb Co. | 91 | 84 | 77 | — | — | |
| Danaher Corp. | 96 | 91 | 88 | — | — | |
| Eli Lilly & Co. | 298 | 237 | 194 | — | — | |
| Gilead Sciences Inc. | 100 | 97 | 89 | — | — | |
| Johnson & Johnson | 154 | 147 | 127 | — | — | |
| Merck & Co. Inc. | 144 | 124 | 159 | — | — | |
| Pfizer Inc. | 149 | 95 | 107 | — | — | |
| Regeneron Pharmaceuticals Inc. | 519 | 562 | 292 | — | — | |
| Thermo Fisher Scientific Inc. | 72 | 79 | 94 | — | — | |
| Vertex Pharmaceuticals Inc. | 214 | 156 | 143 | — | — | |
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 143 | 119 | 117 | — | — | |
| Average Inventory Processing Period, Industry | ||||||
| Health Care | 50 | 46 | 46 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.00 = 365
2 Click competitor name to see calculations.
A consistent decline in inventory efficiency is evident over the five-year period ending December 31, 2023. The operational metrics indicate a progressive slowdown in the rate at which inventory is converted into sales, reflecting a significant shift in short-term operating activity.
- Inventory Turnover
- A steady downward trend is observed in the inventory turnover ratio, which decreased from 1.41 in 2019 to 1.00 by the end of 2023. This continuous reduction suggests a diminishing capacity to cycle through inventory stocks, indicating that the company is turning over its inventory less frequently each year.
- Average Inventory Processing Period
- Correspondingly, the average inventory processing period has increased monotonically. The duration rose from 258 days in 2019 to 365 days in 2023. This represents an extension of the inventory holding period by 107 days over the analyzed timeframe, meaning inventory now remains in the processing cycle for an average of one full year.
The inverse correlation between the turnover ratio and the processing period highlights a weakening of inventory management efficiency. The extension of the processing period to 365 days suggests a potential accumulation of unsold stock or a strategic increase in safety stock levels, both of which typically result in higher carrying costs and reduced liquidity of current assets.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Receivable Collection Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 6.55 | 6.65 | 6.86 | 6.59 | 5.76 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 56 | 55 | 53 | 55 | 63 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 75 | 71 | 65 | — | — | |
| Amgen Inc. | 99 | 82 | 74 | — | — | |
| Bristol-Myers Squibb Co. | 74 | 67 | 65 | — | — | |
| Danaher Corp. | 60 | 57 | 57 | — | — | |
| Eli Lilly & Co. | 97 | 88 | 86 | — | — | |
| Gilead Sciences Inc. | 63 | 65 | 61 | — | — | |
| Johnson & Johnson | 64 | 62 | 59 | — | — | |
| Merck & Co. Inc. | 63 | 58 | 69 | — | — | |
| Pfizer Inc. | 69 | 40 | 51 | — | — | |
| Regeneron Pharmaceuticals Inc. | 158 | 160 | 137 | — | — | |
| Thermo Fisher Scientific Inc. | 70 | 66 | 74 | — | — | |
| Vertex Pharmaceuticals Inc. | 58 | 59 | 55 | — | — | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 74 | 63 | 66 | — | — | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 48 | 44 | 46 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.55 = 56
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals an overall improvement in the efficiency of receivables management between 2019 and 2023, characterized by an initial acceleration in cash conversion followed by a period of stability.
- Receivables Turnover
- A positive trend is observed from 2019 to 2021, where the turnover ratio increased from 5.76 to a peak of 6.86. Following this peak, the ratio experienced a slight contraction, declining to 6.65 in 2022 and further to 6.55 by the end of 2023. Despite the marginal decrease in the final two years, the turnover remains significantly higher than the 2019 baseline, indicating a more efficient conversion of receivables into cash.
- Average Receivable Collection Period
- The collection period demonstrates an inverse relationship with the turnover ratio, decreasing from 63 days in 2019 to a low of 53 days in 2021. A slight increase followed in the subsequent years, rising to 55 days in 2022 and 56 days in 2023. This trajectory indicates that the company successfully reduced its collection cycle by approximately one week over the five-year period.
The data suggests a stabilization of credit management practices. The alignment of the turnover ratio and the collection period from 2021 through 2023 indicates a consistent approach to credit terms and collection efforts, maintaining a working capital cycle that is more streamlined than that observed at the start of the period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Cycle
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 365 | 349 | 305 | 289 | 258 | |
| Average receivable collection period | 56 | 55 | 53 | 55 | 63 | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 421 | 404 | 358 | 344 | 321 | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | 148 | 146 | 130 | — | — | |
| Amgen Inc. | 510 | 363 | 305 | — | — | |
| Bristol-Myers Squibb Co. | 165 | 151 | 142 | — | — | |
| Danaher Corp. | 156 | 148 | 145 | — | — | |
| Eli Lilly & Co. | 395 | 325 | 280 | — | — | |
| Gilead Sciences Inc. | 163 | 162 | 150 | — | — | |
| Johnson & Johnson | 218 | 209 | 186 | — | — | |
| Merck & Co. Inc. | 207 | 182 | 228 | — | — | |
| Pfizer Inc. | 218 | 135 | 158 | — | — | |
| Regeneron Pharmaceuticals Inc. | 677 | 722 | 429 | — | — | |
| Thermo Fisher Scientific Inc. | 142 | 145 | 168 | — | — | |
| Vertex Pharmaceuticals Inc. | 272 | 215 | 198 | — | — | |
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 217 | 182 | 183 | — | — | |
| Operating Cycle, Industry | ||||||
| Health Care | 98 | 90 | 92 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 365 + 56 = 421
2 Click competitor name to see calculations.
The operating cycle exhibits a consistent upward trend, extending from 321 days in 2019 to 421 days by the end of 2023. This expansion indicates a lengthening of the time required to convert initial investments in inventory back into cash through sales and collections.
- Average Inventory Processing Period
- A significant and continuous increase is observed in the inventory processing period, which rose from 258 days in 2019 to 365 days in 2023. This represents a total increase of 107 days over the analyzed period, suggesting a deceleration in inventory turnover and a growing duration of stock retention before sale.
- Average Receivable Collection Period
- The receivable collection period has remained relatively stable with a slight overall improvement. The duration decreased from 63 days in 2019 to 56 days in 2023, reflecting consistent efficiency in credit management and the collection of outstanding payments.
- Operating Cycle Dynamics
- The overall extension of the operating cycle is primarily driven by the substantial increase in the inventory processing period. The slight reduction in the receivable collection period was insufficient to offset the inventory slowdown, resulting in a net increase of 100 days in the total operating cycle over the five-year duration.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Payables Payment Period
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 6.23 | 6.06 | 5.28 | 4.50 | 6.62 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 59 | 60 | 69 | 81 | 55 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 66 | 61 | 60 | — | — | |
| Amgen Inc. | 69 | 90 | 77 | — | — | |
| Bristol-Myers Squibb Co. | 111 | 109 | 108 | — | — | |
| Danaher Corp. | 65 | 67 | 82 | — | — | |
| Eli Lilly & Co. | 134 | 106 | 83 | — | — | |
| Gilead Sciences Inc. | 31 | 58 | 39 | — | — | |
| Johnson & Johnson | 132 | 137 | 135 | — | — | |
| Merck & Co. Inc. | 89 | 89 | 123 | — | — | |
| Pfizer Inc. | 98 | 72 | 66 | — | — | |
| Regeneron Pharmaceuticals Inc. | 122 | 138 | 84 | — | — | |
| Thermo Fisher Scientific Inc. | 41 | 48 | 53 | — | — | |
| Vertex Pharmaceuticals Inc. | 106 | 103 | 79 | — | — | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 86 | 85 | 86 | — | — | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 61 | 63 | 63 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 6.23 = 59
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a period of volatility in accounts payable management beginning in 2020, followed by a consistent return toward baseline efficiency levels through 2023.
- Payables Turnover
- A significant contraction in the payables turnover ratio occurred between 2019 and 2020, falling from 6.62 to 4.50. This decline indicates a slower rate of supplier payment during that period. Subsequently, a steady recovery trend is observed, with the ratio increasing annually to 5.28 in 2021, 6.06 in 2022, and reaching 6.23 by the end of 2023, nearly returning to the 2019 efficiency level.
- Average Payables Payment Period
- The payment period experienced a sharp increase from 55 days in 2019 to a peak of 81 days in 2020, representing a substantial extension of the time taken to settle obligations with suppliers. Following this peak, the payment period contracted consistently over the next three years, decreasing to 69 days in 2021, 60 days in 2022, and finalizing at 59 days in 2023.
The inverse correlation between the turnover ratio and the payment period is evident throughout the analyzed timeframe. The extension of payment terms in 2020 suggests a temporary shift in working capital management or liquidity prioritization. However, the subsequent trend indicates a disciplined transition back to shorter payment cycles, suggesting a normalization of supplier relations and cash flow allocation.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Cash Conversion Cycle
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 365 | 349 | 305 | 289 | 258 | |
| Average receivable collection period | 56 | 55 | 53 | 55 | 63 | |
| Average payables payment period | 59 | 60 | 69 | 81 | 55 | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 362 | 344 | 289 | 263 | 266 | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | 82 | 85 | 70 | — | — | |
| Amgen Inc. | 441 | 273 | 228 | — | — | |
| Bristol-Myers Squibb Co. | 54 | 42 | 34 | — | — | |
| Danaher Corp. | 91 | 81 | 63 | — | — | |
| Eli Lilly & Co. | 261 | 219 | 197 | — | — | |
| Gilead Sciences Inc. | 132 | 104 | 111 | — | — | |
| Johnson & Johnson | 86 | 72 | 51 | — | — | |
| Merck & Co. Inc. | 118 | 93 | 105 | — | — | |
| Pfizer Inc. | 120 | 63 | 92 | — | — | |
| Regeneron Pharmaceuticals Inc. | 555 | 584 | 345 | — | — | |
| Thermo Fisher Scientific Inc. | 101 | 97 | 115 | — | — | |
| Vertex Pharmaceuticals Inc. | 166 | 112 | 119 | — | — | |
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 131 | 97 | 97 | — | — | |
| Cash Conversion Cycle, Industry | ||||||
| Health Care | 37 | 27 | 29 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 365 + 56 – 59 = 362
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a significant upward trajectory over the analyzed five-year period, increasing from 266 days in 2019 to 362 days by the end of 2023. This trend indicates a lengthening of the time required to convert resource inputs into cash flows, reflecting a decrease in overall operational liquidity efficiency.
- Average Inventory Processing Period
- A consistent and substantial increase is observed in the time required to process inventory, which rose from 258 days in 2019 to 365 days in 2023. This steady growth represents the primary driver behind the expansion of the total cash conversion cycle, suggesting an accumulation of stock or a slowing of inventory turnover.
- Average Receivable Collection Period
- The collection of receivables has remained relatively stable and efficient. After an initial decrease from 63 days in 2019 to a low of 53 days in 2021, the period has fluctuated marginally, ending at 56 days in 2023. This stability indicates consistent credit management and reliable customer payment behavior.
- Average Payables Payment Period
- The payment period for payables experienced a peak of 81 days in 2020, followed by a gradual decline to 59 days by 2023. The reduction from the 2020 peak suggests that the company is settling its obligations to suppliers more quickly, which further contributes to the increase in the net cash conversion cycle by reducing the available period of spontaneous financing.
- Cash Conversion Cycle Synthesis
- The overall increase of 96 days in the cash conversion cycle between 2019 and 2023 is fundamentally attributed to the degradation of inventory turnover. While receivable collections have remained optimized, the combined effect of slower inventory movement and a shortened payables payment window has resulted in a more prolonged operating cycle.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?